Katholieke Universiteit Leuven, Ku Leuven R&d

Katholieke Universiteit Leuven

Vib Vzw

Ucb Biopharma Sprl

Springworks Therapeutics, Inc.

Other

Ucb Pharma, S.a.

Ucbbiopharma Srl

Bart Vanderhoydonck

Jean Herman

Qiuya Huang

Piet Herdewijn

James Thomas Reuberson

Daniel James Ford

Steven De Jonghe

Thierry Louat

Ling-Jie Gao

Judi Charlotte Neuss

Helen Tracey Horsley

Anant Ramrao Ghawalkar

Arnaud Marchand

Johan Neyts

Richard Jeremy Franklin

Christophe Pannecouque

Mark Jozef Albert Waer

Pieter Leyssen

Mi-Yeon Jang

Miyeon Jang

Yuan Lin

Thierry Andre Michel Louat

Matthias Versele

Aurélie Candi

Daniel Christopher Brookings

Mark Waer

Claire Louise Kulisa

Wim Smets

Stéphane Spieser

Georg Halder

Stephen L Gwaltney, Ii

Jean Ferdinand Herman

Thierry Andre Louat

Mark Jozef Waer

Thierry André Michel Louat

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD

2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD

A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

Therapeutically active pyrazolo-pyrimidine derivatives

A series of fused bicyclic heteroaromatic derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III&#x3b2; (PI4KIII&#x3b2;) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection. 

Fused bicyclic heteroaromatic derivatives as kinase inhibitors

A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III&#x3b2; (PI4KIII&#x3b2;) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claimor as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovints. 

Antiviral activity of novel bicyclic heterocycles

Compounds that bind to phosphatidylinositol-4-kinase III&#x3b2; (PI4KIII&#x3b2;) and inhibit the binding of PI4KIII&#x3b2; to its substrate and/or inhibit PI4KIII&#x3b2; activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII&#x3b2; activity, is also disclosed.

Autoimmune and inflammatory disorder therapy

A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

Therapeutically active fused pyrimidine derivatives

The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R, R, R, R, R, R, R, R, R, R, and Rare as defined in the claim. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections. 

Thiazolopyrimidine modulators as immunosuppressive agents

The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claimor as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. 

Antiviral activity of bicyclic heterocycles

Growing community of inventors

Diest, Belgium

Bart Vanderhoydonck